Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05253495 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma

Study acronym: RADICAL
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Site details revised at 2 of 3 sitesv5
  2. Study sites: 1 to 3v4
  3. Interventions: AD CP (Drug), Bv-AVD-R (Drug), Bv-AVD-R 1 and 2: COHORT IIa (Drug), Bv-NAVD-R, Cycle 1-2 (Drug), Bv-NVD-R, Cycle 1-2 (Drug), Bv-NVD-R… to AD CP (Drug), Bv-AVD-R (Drug), Bv-AVD-R 1 and 2: COHORT IIa (Drug), Bv-NAVD-R, Cycle 1-2 (Drug), Bv-NVD-R, Cycle 1-2 (Drug), Bv-NVD-R…
    • Study description expanded, about 90 words
    v3
  4. Primary endpoints revised (2)
    • Interventions: AD CP (Drug), Bv-AVD-R (Drug), Bv-AVD-R 1 and 2: COHORT IIa (Drug), Bv-NAVD-R, Cycle 1-2 (Drug), Bv-NVD-R, Cycle 1-2 (Drug), Bv-NVD-R… to AD CP (Drug), Bv-AVD-R (Drug), Bv-AVD-R 1 and 2: COHORT IIa (Drug), Bv-NAVD-R, Cycle 1-2 (Drug), Bv-NVD-R, Cycle 1-2 (Drug), Bv-NVD-R…
    • Study title shortened, about 8 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The addition of targeted immunotherapy will be safe and well tolerated and facilitate the reduction of anthracycline exposure while preserving lymphoma disease control in children, adolescents and young adults (CAYA) with mature B-cell non-Hodgkin lymphoma (MB-NHL) and classical Hodgkin lymphoma (cHL).
Trial Details
NCT Number NCT05253495
Lead Sponsor New York Medical College
Conditions
(from sponsor)		 Non-hodgkin Lymphoma, Hodgkin Lymphoma
Related terms Hodgkin Disease, Lymphoma, Non-Hodgkin
Enrollment 80 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov